GLP-1 and Kidney Health: Protection, and the Dehydration Warning

Two findings about GLP-1s and kidneys sit side by side, and publishing either one alone would mislead you in opposite directions. In the FLOW trial, semaglutide 1.0 mg reduced major kidney events by 24% in adults with type 2 diabetes and chronic kidney disease. Separately, FDA labelling across the class warns of serious kidney injury from dehydration, in some cases requiring haemodialysis, with most reported cases following nausea, vomiting or diarrhoea. Both are correct. They operate on different timescales through different mechanisms, and the acute one is the one you can act on this week. FLOW's benefit is specific to a population and a dose, and does not transfer automatically to obesity dosing in people without diabetes.

The acute risk, and what to watch for

The labelled danger is short and mechanical. Vomiting or diarrhoea reduces circulating volume, kidney perfusion falls, and filtration drops with it. That is pre-renal acute kidney injury, reversible if volume is restored early. Most postmarketing acute kidney injury reports on this class followed exactly that sequence.

Signs that warrant contacting a clinician the same day:

• Vomiting or diarrhoea for more than about a day, particularly if fluids will not stay down
• Reduced urine output, very dark urine, or not passing urine
• Swelling, breathlessness or confusion
• Dizziness on standing alongside poor fluid intake
• Any of the above if you already have kidney disease, where the threshold to make contact should be lower

The FLOW trial

FLOW randomised 3,533 adults with type 2 diabetes and chronic kidney disease to semaglutide 1.0 mg or placebo. It reported a 24% reduction in major kidney events, an 18% reduction in major cardiovascular events, and a 20% reduction in all-cause death.

Those are hard endpoints rather than surrogate markers, which is what makes the trial matter. Slowing decline in a lab value is a weaker result than reducing the number of people who reach kidney failure or die, and FLOW delivered the latter.

The kidney benefit held irrespective of baseline chronic kidney disease severity, whether measured by eGFR or by urinary albumin-to-creatinine ratio. The effects were also observed both with and without concomitant SGLT2 inhibitor use, which matters because SGLT2 inhibitors are themselves established kidney protection in this population, so the question of whether semaglutide adds anything on top of them is a real one. In FLOW it did.

Who FLOW applies to

This section exists because the FLOW result gets quoted far outside the population it was measured in. The trial enrolled people with type 2 diabetes and chronic kidney disease, and it used semaglutide 1.0 mg, the diabetes dose rather than the weight-management dose.

It does not establish the same kidney benefit in people without diabetes, and it does not establish it at obesity dosing. Weight loss and blood pressure reduction plausibly help kidneys in anyone, but plausible is not the same as demonstrated in a randomised trial with hard endpoints.

If you are taking a GLP-1 for weight management and do not have diabetes, FLOW is encouraging background rather than a result about you.

How the two facts fit together

There is no contradiction here once you separate the timescales.

Chronic kidney damage in type 2 diabetes is driven by glomerular hyperfiltration, albuminuria, inflammation and fibrosis, accumulating over years. Semaglutide appears to slow that through improved glycaemic control, lower blood pressure, weight reduction and probable direct anti-inflammatory effects on the kidney.

The acute injury runs by a completely different route over hours to days. Volume depletion from a GI illness drops renal perfusion pressure and filtration falls. One is a slow structural process being slowed down. The other is an acute perfusion problem. A drug can influence both in opposite directions without either finding being wrong.

Monitoring

Labelling advises monitoring renal function in patients who report severe adverse gastrointestinal reactions that could cause severe dehydration, and notes that this applies particularly at initiation and during dose escalation, when those reactions cluster.

In practice that means a blood test after a significant episode of vomiting or diarrhoea, and it is reasonable to ask your prescriber directly what your monitoring schedule is rather than assuming one exists. Someone with pre-existing kidney disease will usually be on a more frequent schedule than someone without.

One quirk worth knowing about. Creatine supplementation raises measured serum creatinine without any kidney injury, purely because creatine converts to creatinine. If you take creatine, say so before bloods, or you risk an alarming result and an unnecessary investigation. Our page on creatine covers this.

Kidney impairment and dosing

Dose adjustment questions in kidney impairment belong with a prescriber and depend on the specific product and the degree of impairment. This page will not give a number, because the right one depends on details of your kidney function that only your clinician has.

What is generally true is that reduced kidney function raises the stakes of a dehydrating illness rather than changing day-to-day treatment. The plan you want in place is the illness plan, not a self-managed dose adjustment.

Sick-day thinking

There is no published GLP-1-specific sick-day rule set of the kind that exists for insulin or SGLT2 inhibitors. What anchors the advice is the labelling warning and your prescriber's judgement.

The practical version is short. Get fluid in early, do not wait to see whether a vomiting illness settles by itself, and treat reduced urine output as a signal rather than an inconvenience. Whether to take, delay or skip a dose during illness is a prescriber decision. Our sick-day page goes through this in more detail.

Not medical advice

This page reports published trial results and FDA labelling language. It is general educational information, not advice about your kidneys, your dose or your monitoring. If you have kidney disease, use it as a prompt for a conversation with the clinician who manages it.

The evidence, one row per claim

Sources

1. FLOW trial analyses (PMC)
2. Cleveland Clinic Journal of Medicine, FLOW ASN 2024 coverage
3. OZEMPIC US Prescribing Information, FDA
4. FLOW prespecified analysis by SGLT2 inhibitor use (PMC)

Keep reading

• GLP-1 and Hydration: Why Fluid Intake Drops and Why It MattersA soft wellness topic with a hard regulatory warning behind it: dehydration following GI symptoms is the docum
• GLP-1 and Diabetes: What Differs Between the T2D and Obesity IndicationsOzempic and Wegovy are the same molecule with different indications. The part that can hurt you is what happen
• GLP-1 Sick Days: Vomiting, Diarrhoea and When to Get HelpThe labelled harm chain is short: GI symptoms, then dehydration, then kidney injury. Interrupting it early is
• GLP-1 and Creatine: Does It Help Preserve Muscle?No GLP-1-specific research exists. The honest page covers creatine's own evidence, the water-weight artefact a
• GLP-1 and GI Side Effects: Nausea, Constipation and RefluxGI effects are the dominant labelled adverse reactions, inseparable from how the drug works, and concentrated